Pharming Group N.V. Reports Q1 2025 Results

Ticker: PHAR · Form: 6-K · Filed: 2025-03-20T00:00:00.000Z

Sentiment: neutral

Topics: financial-results, 6-K, pharmaceuticals

TL;DR

Pharming Group N.V. dropped Q1 2025 results on 3/20/25. Check the 6-K for details.

AI Summary

Pharming Group N.V. announced its first quarter 2025 financial results on March 20, 2025. The company, headquartered in Leiden, The Netherlands, is a pharmaceutical preparations firm.

Why It Matters

This filing provides investors with an update on Pharming Group's financial performance and operational status for the first quarter of 2025.

Risk Assessment

Risk Level: low — This is a routine financial results filing with no immediately apparent negative or positive catalysts.

Key Players & Entities

FAQ

What is the primary business of Pharming Group N.V.?

Pharming Group N.V. is in the Pharmaceutical Preparations industry, SIC code 2834.

When was this Form 6-K filed?

This Form 6-K was filed on March 20, 2025.

What is the company's principal executive office address?

The company's principal executive offices are located at Darwinweg 24, 2333 CR Leiden, The Netherlands.

Does Pharming Group N.V. file annual reports under Form 20-F?

Yes, Pharming Group N.V. indicates it files annual reports under Form 20-F.

What exhibit is furnished with this Form 6-K?

Exhibit 99.1, a press release of Pharming Group N.V. dated March 20, 2025, is furnished with this Form 6-K.

From the Filing

0001828316-25-000014.txt : 20250320 0001828316-25-000014.hdr.sgml : 20250320 20250320101239 ACCESSION NUMBER: 0001828316-25-000014 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250320 FILED AS OF DATE: 20250320 DATE AS OF CHANGE: 20250320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharming Group N.V. CENTRAL INDEX KEY: 0001828316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39822 FILM NUMBER: 25754796 BUSINESS ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR BUSINESS PHONE: 31 (0)71 5247 400 MAIL ADDRESS: STREET 1: DARWINWEG 24 CITY: LEIDEN STATE: P7 ZIP: 2333 CR FORMER COMPANY: FORMER CONFORMED NAME: Pharming Group Group N.V. DATE OF NAME CHANGE: 20201014 6-K 1 pharminggroupannouncesfirs.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March Commission File Number: 001-39822 Pharming Group N.V. (Exact Name of Registrant as Specified in Its Charter) Darwinweg 24 2333 CR Leiden The Netherlands (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Pharming Group N.V., or the Company, dated March 20, 2025. EXHIBIT INDEX Exhibit No. Description 99.1 Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Pharming Group N.V. By: /s/ Fabrice Chouraqui Name: Fabrice Chouraqui Title: CEO Date: March 20, 2025 Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the first patient has been dosed in a Phase II, proof of concept, clinical trial evaluating leniolisib in common variable immunodeficiency (CVID) patients with immune dysregulation. The Phase II clinical trial is a single arm, open-label, dose range-finding, multi-center study to be conducted in approximately 20 patients 12 years of age and older. The trial will include patients with a CVID diagnosis, a requirement for evidence of lymphoproliferation, and at least one additional clinical manifestation of immune dysregulation, including interstitial lung disease, autoimmune cytopenias, or enteropathy. The objectives for the trial are to assess safety and tolerability, pharmacokinetics, pharmacodynamics, and explore clinical efficacy of leniolisib in the targeted CVID with immune dysregulation population. The trial has been designed to inform a subsequent Phase III program.

View on Read The Filing